Psychomotor Impairment — Cannabis Effects on Driving-related Skills of Young Drivers
Citation(s)
Adlaf EM, Begin P, Sawka E Canadian Addiction Survey (CAS): A national survey of Canadians' use of alcohol and other drugs: Prevalence of use and related harms: Detailed report. Ottawa, Canada: Canadian Cenre for Substance Abuse 2005
Adlaf EM, Mann RE, Paglia A Drinking, cannabis use and driving among Ontario students. CMAJ. 2003 Mar 4;168(5):565-6.
Asbridge M, Poulin C, Donato A Motor vehicle collision risk and driving under the influence of cannabis: evidence from adolescents in Atlantic Canada. Accid Anal Prev. 2005 Nov;37(6):1025-34. Epub 2005 Jun 29.
Brault M, Dussault C, Bouchard J, Lemire AM The contribution of alcohol and other drugs among fatally injured drivers in Quebec: final results. Société de l'assurance automobile du Quebec 2002. Available from: http://www.saaq.gouv.qc.ca/publications/dossiers_etudes/drogue_an.pdf
Chipman ML, Macdonald S, Mann RE Being "at fault" in traffic crashes: does alcohol, cannabis, cocaine, or polydrug abuse make a difference? Inj Prev. 2003 Dec;9(4):343-8.
Cone EJ, Huestis MA Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. Ther Drug Monit. 1993 Dec;15(6):527-32. Review.
Fischer B, Rodopoulos J, Rehm J, Ivsins A Toking and driving: Characteristics of Canadian university students who drive after cannabis use - an exploratory pilot study. Drugs Ed Prev Policy 13:179-87, 2006
Harder S, Rietbrock S Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. Int J Clin Pharmacol Ther. 1997 Apr;35(4):155-9.
Heishman SJ, Huestis MA, Henningfield JE, Cone EJ Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. Pharmacol Biochem Behav. 1990 Nov;37(3):561-5.
Laumon B, Gadegbeku B, Martin JL, Biecheler MB; SAM Group Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ. 2005 Dec 10;331(7529):1371. Epub 2005 Dec 1. Erratum in: BMJ. 2006 Jun 3;332(7553):1298.
McGuire F, Dawe M, Shield KD, Rehm J, Fishcher B Driving under the influence of cannabis or alcohol in a cohort of high-frequency cannabis users: prevalence and reflections on current interventions. Canadian Journal of Criminology and Criminal Justice 53(2): 247-259, 2011
McLaren J, Swift W, Dillon P, Allsop S Cannabis potency and contamination: a review of the literature. Addiction. 2008 Jul;103(7):1100-9. doi: 10.1111/j.1360-0443.2008.02230.x. Epub 2008 May 20. Review.
O'Malley PM, Johnston LD Drugs and driving by American high school seniors, 2001-2006. J Stud Alcohol Drugs. 2007 Nov;68(6):834-42.
Pope HG Jr, Gruber AJ, Yurgelun-Todd D The residual neuropsychological effects of cannabis: the current status of research. Drug Alcohol Depend. 1995 Apr;38(1):25-34. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
